<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844113</url>
  </required_header>
  <id_info>
    <org_study_id>Car-PVD</org_study_id>
    <nct_id>NCT03844113</nct_id>
  </id_info>
  <brief_title>Carnosine for Peripheral Vascular Disease</brief_title>
  <acronym>Car-PVD</acronym>
  <official_title>Carnosine for Peripheral Vascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monash Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Monash University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesise that a home-based standardised exercise intervention with 2g of&#xD;
      carnosine daily for 6 months will improve walking endurance in 104 patients with PVD aged&#xD;
      40-80 years compared to placebo and exercise through stabilisation of HIF1-α in the ischaemic&#xD;
      leg.&#xD;
&#xD;
      Aims&#xD;
&#xD;
      Aim 1: Determine whether in patients with PVD, carnosine in addition to exercise improves:&#xD;
&#xD;
        1. walking endurance (6-min walk test; primary outcome);&#xD;
&#xD;
        2. initial claudication distance (ICD), and absolute claudication distance (ACD;&#xD;
           treadmill), cadence, resting and exercise ABI; and&#xD;
&#xD;
        3. central blood pressure, endothelial function, arterial (aortic) stiffness, lipid&#xD;
           profile; and&#xD;
&#xD;
        4. quality of life as determined by EuroQol-5D (all secondary outcomes).&#xD;
&#xD;
        5. Improve cognitive function (global cognitive score formed by a composite of 7 cognitive&#xD;
           tests)&#xD;
&#xD;
      Aim 2: Delineate the mechanisms by which carnosine improves walking endurance:&#xD;
&#xD;
        1. protein expression of pro-angiogenic and carnosine related genes, including carnosine&#xD;
           transporters in the skeletal muscle biopsies, EPCs in peripheral blood and quantitative&#xD;
           proteomic studies.&#xD;
&#xD;
        2. other mechanisms demonstrated in animal studies including plasma inflammatory markers,&#xD;
           serum and urinary advanced glycation (AGE) and lipoxidation (ALE) end-products (tertiary&#xD;
           outcomes).&#xD;
&#xD;
      This trial will provide evidence for use of carnosine as a therapeutic intervention for PVD&#xD;
      patients and, if positive, will have immediate clinical application.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral vascular disease (PVD) has high prevalence of 10-15% in Australia and is caused by&#xD;
      atherosclerotic occlusion of the arteries supplying the lower extremities which reduces blood&#xD;
      flow and leads to intermittent claudication and critical limb ischaemia. No effective&#xD;
      medication is currently available. Although surgical or endovascular revascularisation are&#xD;
      available treatments, not all patients are suitable for the procedure, and grafts can fail,&#xD;
      and dilated arteries can restenose. Structured exercise, both supervised and home-based,&#xD;
      improves walking endurance in patients with PVD to a similar extent as revascularisation and&#xD;
      effects are longer lasting but the pain associated with exercise is a major limitation.&#xD;
      Therefore, there is a need to develop safe interventions synergistic with exercise that can&#xD;
      prompt revascularisation and preserve limb viability.&#xD;
&#xD;
      Angiogenesis plays an essential role for recovery from critical limb ischaemia. Hypoxia&#xD;
      inducible factor 1α (HIF1-α), a master regulator of angiogenic genes, has been implicated .&#xD;
      Under normal conditions, HIF1-α is targeted for proteasomal degradation through the activity&#xD;
      of prolyl hydroxylases (PHDs). PHDs require iron for their activity and their inactivation by&#xD;
      metal chelators or pharmacological inhibitors stabilises HIF1-α and has been shown to improve&#xD;
      blood flow in the ischaemic limb. However, metal chelators cannot be used as an intervention&#xD;
      due to their toxicity.&#xD;
&#xD;
      Recent studies have shown that supplementation of carnosine (β-alanyl-L-histidine), a&#xD;
      naturally occurring histidyl dipeptide in skeletal muscle with an excellent safety profile,&#xD;
      improves exercise performance in athletes as well as in patients with chronic heart failure.&#xD;
      The investigators and others have shown that carnosine supplementation also improves&#xD;
      cardiometabolic risk factors. No clinical trial has yet to investigate whether carnosine&#xD;
      improves walking endurance in patients with PVD. Carnosine has anti-inflammatory,&#xD;
      antioxidative, anti-glycating and anti-atherosclerotic properties. It also has the ability to&#xD;
      chelate metals, form conjugates with reactive aldehydes, and has lactate buffering capacity.&#xD;
      In addition, carnosine has been found to be very effective in reducing ischaemia-reperfusion&#xD;
      damage in several organs. Our preliminary results using a murine model of hind limb ischaemia&#xD;
      (HLI) showed that administration of carnosine over 21 days increased HIF1-a and VEGF levels&#xD;
      in the ischaemic muscle and improved tissue perfusion. Furthermore, mobilisation of&#xD;
      pro-angiogenic endothelial progenitor cells (EPCs) and the ambulatory movement were increased&#xD;
      in carnosine treated HLI mice compared to controls. The investigators propose a randomised&#xD;
      clinical trial to investigate whether administration of carnosine for 6-month in addition to&#xD;
      exercise could improve walking endurance and quality of life in patients with PVD compared to&#xD;
      placebo and exercise.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>parallel assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>walking endurance</measure>
    <time_frame>6 months</time_frame>
    <description>change in walking endurance (6-min walk test)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant will be given a daily oral dose 2 g of carnosine for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each participant will be given a daily oral dose 2 g of placebo for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carnosine</intervention_name>
    <description>Each participant will be given a daily oral dose 2 g of carnosine for 6 months</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Pure Carnosine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;=40or &lt;80 years&#xD;
&#xD;
          -  Clinical diagnosis Peripheral Vascular disease&#xD;
&#xD;
          -  Rutherford Grade 1-3&#xD;
&#xD;
          -  No significant kidney, cardiovascular, haematological, respiratory, gastrointestinal,&#xD;
             or central nervous system disease, as well as no psychiatric disorders, no active&#xD;
             cancer within the last five years; no presence of acute inflammation (by history,&#xD;
             physical or laboratory examination)&#xD;
&#xD;
          -  Intermittent claudication on treadmill between 30m and 200m&#xD;
&#xD;
          -  Ankle Brachial index 0.6-1 at rest with minimum post exercise drop in ABI of 0.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 40 or &gt; 80 years&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Limb threatening ischaemia- Rutherford grades 4-6, manifested by ischaemic rest pain,&#xD;
             ulceration, or gangrene; acute limb-threatening ischaemia&#xD;
&#xD;
          -  lower limb surgical or endovascular interventions in the preceding 6 months&#xD;
&#xD;
          -  planned lower limb endovascular or surgical intervention within the next 6 months on&#xD;
             either limb&#xD;
&#xD;
          -  taking medication for PVD (Cilostazol and Pentoxifylline)&#xD;
&#xD;
          -  inability to complete the treadmill walking test for reasons other than claudication&#xD;
&#xD;
          -  myocardial infarction within last 3 months&#xD;
&#xD;
          -  deep vein thrombosis within 3 months&#xD;
&#xD;
          -  estimated life expectancy &lt; 1 year&#xD;
&#xD;
          -  alcohol and illicit drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbora deCourten, MD,PHD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University and Monash Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbora deCourten, MD,PHD,MPH</last_name>
    <phone>+610385722651</phone>
    <email>barbora.decourten@monash.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monash Centre for Health Research and Implementation</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbora de Courten, MD,PHD,MPH</last_name>
      <phone>+61 3 857 22651</phone>
      <email>barbora.decourten@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Barbora de Courten, MD,PHD,MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Buckenham, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>December 26, 2020</last_update_submitted>
  <last_update_submitted_qc>December 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Monash University</investigator_affiliation>
    <investigator_full_name>Barbora de Courten</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>carnosine</keyword>
  <keyword>peripheral arterial disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

